Prion Diseases

CONTINUUM Lifelong Learning in Neurology

Volumn 21, Issue 6, 2015, Pages 1612-1638

  Geschwind, Michael D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CLINICAL FEATURE; CREUTZFELDT JAKOB DISEASE; DIAGNOSTIC TEST; DIFFUSION WEIGHTED IMAGING; DISEASE CLASSIFICATION; ELECTROENCEPHALOGRAPHY; FATAL FAMILIAL INSOMNIA; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GERSTMANN STRAUSSLER SCHEINKER SYNDROME; HUMAN; KURU; MALE; MIDDLE AGED; PRION DISEASE; REVIEW; SYMPTOMATOLOGY; VARIANT CREUTZFELDT JAKOB DISEASE; GENETICS; PATHOPHYSIOLOGY; PRION DISEASES;

HUMANS; PRION DISEASES;

EID: 84949646001     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/CON.0000000000000251     Document Type: Review

References (79)

1. Jakob A. Concerning a disorder of the central nervous system clinically resembling multiple sclerosis with remarkable anatomic findings (spastic pseudosclerosis). Report of a fourth case. Alzheimer Dis Assoc Disord 1989;3(1-2):26-45.
2. Creutzfeldt HG. On a particular focal disease of the central nervous system (preliminary communication), 1920. Alzheimer Dis Assoc Disord 1989;3(1-2):3-25.
3. Gibbs CJ Jr. Spongiform encephalopathies-slow, latent, and temperate virus infections-in retrospect. In: Prusiner SB, Collinge J, Powell J, et al, eds. Prion diseases of humans and animals. London: Ellis Horwood, 1992:53-62.
4. Katscher F. It's Jakob's disease, not Creutzfeldt's. Nature 1998;393(6680):11. doi:10.1038/29862.
5. Prusiner SB. Prions. Proc Natl Acad Sci U S A 1998;95(23):13363-13383. doi:10.1073/pnas.95.23.13363.
6. Bechtel K, Geschwind MD. Ethics in prion disease. Prog Neurobiol 2013;110:29-44. doi:10.1016/j.pneurobio.2013.07.001.
7. Soto C. Prion hypothesis: the end of the controversy? Trends Biochem Sci 2011;36(3): 151-158. doi:10.1016/j.tibs.2010.11.001.
8. Moreno JA, Halliday M, Molloy C, et al. Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci Transl Med 2013;5(206):206ra138. doi:10.1126/scitranslmed.3006767.
9. Paterson RW, Takada LT, Geschwind MD. Diagnosis and treatment of rapidly progressive dementias. Neurol Clin Pract 2012;2(3): 187-200. doi:10.1212/CPJ.0b013e31826b2ae8.
10. Geschwind MD. Rapidly progressive dementia: prion diseases and other rapid dementias. Continuum (Minneap Minn) 2010;16(2 Dementia):31-56. doi:10.1212/01.CON.0000368211.79211.4c.
11. Maddox RA, Person M, Minino A, et al. P.85: improving Creutzfeldt-Jakob disease incidence estimates by incorporating results of neuropathological analyses, United States, 2003-2011. Presented at Prion 2015 International Research Congress, May 26-29. Prion 2015;9:S55-S56.
12. Brown K, Mastrianni JA. The prion diseases. J Geriatr Psychiatry Neurol 2010;23(4): 277-298. doi:10.1177/0891988710383576.
13. Puoti G, Bizzi A, Forloni G, et al. Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurol 2012;11(7): 618-628. doi:10.1016/S1474-4422(12)70063-7.
14. Collins SJ, Sanchez-Juan P, Masters CL, et al. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain 2006;129(pt 9):2278-2287. doi:http://dx.doi.org/10.1093/brain/awl159 2278-2287.
15. World Health Organization. Global surveillance, diagnosis and therapy of human transmissible spongiform encephalopathies: Report of a WHO consultation Geneva, Switzerland 9-11 February 1998. Geneva, Switzerland: World Health Organization, 1998.
16. Vitali P, Maccagnano E, Caverzasi E, et al. Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. Neurology 2011;76(20): 1711-1719. doi:10.1212/WNL.0b013e31821a4439.
17. Geschwind MD, Josephs KA, Parisi JE, Keegan BM. A 54-year-old man with slowness of movement and confusion. Neurology 2007;69(19):1881-1887. doi:10.1212/01.wnl.0000290370.14036.69.
18. Forner SA, Takada LT, Bettcher BM, et al. Comparing CSF biomarkers and brain MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease. Neurol Clin Pract 2015;5(2):116-125. doi:10.1212/CPJ.0000000000000111.
19. Brown P, Cathala F, Castaigne P, Gajdusek C. Creutzfeldt-Jakob disease: clinical analysis of a consecutive series of 230 neuropathologically verified cases. Ann Neurol 1986;20(5):597-602. doi:10.1002/ana.410200507.
20. Rabinovici GD, Wang PN, Levin J, et al. First symptom in sporadic Creutzfeldt-Jakob disease. Neurology 2006;66(2):286-287. doi:10.1212/01.wnl.0000196440.00297.67.
21. Will RG, Matthews WB. A retrospective study of Creutzfeldt-Jakob disease in England and Wales 1970-79. I: clinical features. J Neurol Neurosurg Psychiatry 1984;47(2):134-140.
22. Tsuji S, Kuroiwa Y. Creutzfeldt-Jakob disease in Japan. Neurology 1983;33:1503-1506.
23. Paterson RW, Torres-Chae CC, Kuo AL, et al. Differential diagnosis of Jakob-Creutzfeldt disease. Arch Neurol 2012;69(12):1578-1582. doi:10.1001/2013.jamaneurol.79.
24. Lloyd SE, Mead S, Collinge J. Genetics of prion diseases. Curr Opin Genet Dev 2013;23(3): 345-351. doi:10.1016/j.gde.2013.02.012.
25. Steinhoff BJ, Zerr I, Glatting M, et al. Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease. Ann Neurol 2004;56(5):702-708. doi:10.1002/ana.20261.
26. Young GS, Geschwind MD, Fischbein NJ, et al. Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis. AJNR Am J Neuroradiol 2005;26(6):1551-1562.
27. Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 2009;132(pt 10): 2659-2668. doi:10.1093/brain/awp191.
28. Geschwind MD, Kuryan C, Cattaruzza T, et al. Brain MRI in sporadic Jakob-Creutzfeldt disease is often misread. Neurology 2010;74:A213.
29. Carswell C, Thompson A, Lukic A, et al. MRI findings are often missed in the diagnosis of Creutzfeldt-Jakob disease. BMC Neurol 2012;12:153. doi:10.1186/1471-2377-12-153.
30. Green A, Sanchez-Juan P, Ladogana A, et al. CSF analysis in patients with sporadic CJD and other transmissible spongiform encephalopathies. Eur J Neurol 2007;14(2):121-124. doi:10.1111/j.1468-1331. 2006.01630.x.
31. Kim MO, Geschwind MD. Clinical update of Jakob-Creutzfeldt disease. Curr Opin Neurol 2015;28(3):302-310. doi:10.1097/WCO.0000000000000197.
32. Stoeck K, Sanchez-Juan P, Gawinecka J, et al. Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain 2012;135(pt 10): 3051-3061. doi:10.1093/brain/aws238.
33. Coulthart MB, Jansen GH, Olsen E, et al. Diagnostic accuracy of cerebrospinal fluid protein markers for sporadic Creutzfeldt-Jakob disease in Canada: a 6-year prospective study. BMC Neurol 2011;11:133. doi:10.1186/1471-2377-11-133.
34. Hamlin C, Puoti G, Berri S, et al. A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease. Neurology 2012;79(6):547-552. doi:10.1212/WNL.0b013e318263565f.
35. Muayqil T, Gronseth G, Camicioli R. Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2012;79(14):1499-1506. doi:10.1212/WNL.0b013e31826d5fc3.
36. Schmitz M, Ebert E, Stoeck K, et al. Validation of 14-3-3 protein as a marker in sporadic Creutzfeldt-Jakob disease diagnostic (published online ahead of print May 7, 2015). Mol Neurobiol. doi:10.1007/s12035-015-9167-5.
37. Kovacs GG, Puopolo M, Ladogana A, et al. Genetic prion disease: the EUROCJD experience. Hum Genet 2005;118(2): 166-174. doi:10.1007/s00439-005-0020-1.
38. Mead S, Gandhi S, Beck J, et al. A novel prion disease associated with diarrhea and autonomic neuropathy. N Engl J Med 2013;369(20):1904-1914. doi:10.1056/NEJMoa1214747.
39. Vitali P, Migliaccio R, Agosta F, et al. Neuroimaging in dementia. Semin Neurol 2008; 28(4):467-483. doi:10.1055/s-0028-1083695.
40. Sanchez-Juan P, Green A, Ladogana A, et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2006;67(4):637-643. doi:10.1212/01.wnl.0000230159.67128.00.
41. Sano K, Satoh K, Atarashi R, et al. Early detection of abnormal prion protein in genetic human prion diseases now possible using real-time QUIC assay. PLoS One 2013;8(1):e54915. doi:10.1371/journal.pone.0054915.
42. Takao M, Kadowaki T, Tomita Y, et al. 'Hot-cross bun sign' of multiple system atrophy. Intern Med 2007;46(22):1883. doi:http://doi.org/10.2169/internalmedicine.46.0514.
43. Webb TE, Poulter M, Beck J, et al. Phenotypic heterogeneity and genetic modification of P102L inherited prion disease in an international series. Brain 2008;131(pt 10): 2632-2646. doi:10.1093/brain/awn202.
44. Rogaeva E, Zadikoff C, Ponesse J, et al. Childhood onset in familial prion disease with a novel mutation in the PRNP gene. Arch Neurol 2006;63(7):1016-1021. doi:10.1001/archneur.63.7.1016.
45. McLean CA, Storey E, Gardner RJ, et al. The D178N (cis-129M) ''fatal familial insomnia'' mutation associated with diverse clinicopathologic phenotypes in an Australian kindred. Neurology 1997;49(2): 552-558. doi:10.1212/WNL.49.2.552.
46. Cortelli P, Perani D, Parchi P, et al. Cerebral metabolism in fatal familial insomnia: relation to duration, neuropathology, and distribution of protease-resistant prion protein. Neurology 1997;49(1):126-133. doi:10.1212/WNL.49.1.126.
47. Haïk S, Galanaud D, Linguraru MG, et al. In vivo detection of thalamic gliosis: a pathoradiologic demonstration in familial fatal insomnia. Arch Neurol 2008;65(4):545-549. doi:10.1001/archneur.65.4.545.
48. Kim MO, Cali I, Oehler A, et al. Genetic CJD with a novel E200G mutation in the prion protein gene and comparison with E200K mutation cases. Acta Neuropathol Commun 2013;1:80. doi:10.1186/2051-5960-1-80.
49. Watts JC, Giles K, Serban A, et al. Modulation of Creutzfeldt-Jakob disease prion propagation by the A224V mutation (published online ahead of print June 20, 2015). Ann Neurol doi:10.1002/ana.24463.
50. Uflacker A, Doraiswamy PM, Rechitsky S, et al. Preimplantation genetic diagnosis (PGD) for genetic prion disorder due to F198S mutation in the PRNP gene. JAMA Neurol 2014;71(4):484-486. doi:10.1001/jamaneurol.2013.5884.
51. Asante EA, Smidak M, Grimshaw A, et al. A naturally occurring variant of the human prion protein completely prevents prion disease. Nature 2015;522(7557):478-481. doi:10.1038/nature14510.
52. Heath CA, Cooper SA, Murray K, et al. Diagnosing variant Creutzfeldt-Jakob disease: a retrospective analysis of the first 150 cases in the UK. J Neurol Neurosurg Psychiatry 2011;82(6):646-651. doi:10.1136/jnnp.2010.232264.
53. Maheshwari A, Fischer M, Gambetti P, et al. Recent US case of variant Creutzfeldt-Jakob disease-global implications. Emerg Infect Dis 2015;21(5):750-759. doi:10.3201/eid2105.142017.
54. Heath CA, Cooper SA, Murray K, et al. Validation of diagnostic criteria for variant Creutzfeldt-Jakob disease. Ann Neurol 2010;67(6):761-770. doi:10.1002/ana.21987.
55. Martindale J, Geschwind MD, De Armond S, et al. Sporadic Creutzfeldt-Jakob disease mimicking variant Creutzfeldt-Jakob disease. Arch Neurol 2003;60(5):767-770. doi:10.1001/archneur.60.5.767.
56. Hill AF, Butterworth RJ, Joiner S, et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999;353(9148): 183-189. doi:10.1016/S0140-6736(98)12075-5.
57. Ironside JW. Variant Creutzfeldt-Jakob disease: an update. Folia Neuropathol 2012;50(1):50-56.
58. Knight R. The risk of transmitting prion disease by blood or plasma products. Transfus Apher Sci 2010;43(3):387-391. doi:10.1016/j.transci.2010.09.003.
59. Salmon R. How widespread is variant Creutzfeldt-Jakob disease? BMJ 2013;347:f5994. doi:10.1136/bmj.f5994.
60. de Marco MF, Linehan J, Gill ON, et al. Large-scale immunohistochemical examination for lymphoreticular prion protein in tonsil specimens collected in Britain. J Pathol 2010;222(4):380-387. doi:10.1002/path.2767.
61. Clewley JP, Kelly CM, Andrews N, et al. Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: cross sectional opportunistic survey. BMJ 2009;338:b1442. doi:10.1136/bmj.b1442.
62. Brown P, Brandel JP, Preece M, Sato T. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology 2006;67(3):389-393. doi:10.1212/01.wnl.0000231528.65069.3f.
63. Brown P, Brandel JP, Sato T, et al. Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg Infect Dis 2012;18(6):901-907. doi:10.3201/eid1806.120116.
64. Will RG. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br Med Bull 2003;66:255-265.
65. Abrams JY, Schonberger LB, Belay ED, et al. Lower risk of Creutzfeldt-Jakob disease in pituitary growth hormone recipients initiating treatment after 1977. J Clin Endocrinol Metab 2011;96(10):E1666YE1169. doi:10.1210/jc.2011-1357.
66. Appleby BS, Lu M, Bizzi A, et al. Iatrogenic Creutzfeldt-Jakob disease from commercial cadaveric human growth hormone. Emerg Infect Dis 2013;19(4):682-684. doi:10.3201/eid1904.121504.
67. Cali I, Miller CJ, Parisi JE, et al. Distinct pathological phenotypes of Creutzfeldt-Jakob disease in recipients of prion-contaminated growth hormone. Acta Neuropathol Commun 2015;3(1):37. doi:10.1186/s40478-015-0214-2.
68. Lewis AM, Yu M, De Armond SJ, et al. Human growth hormone-related iatrogenic Creutzfeldt-Jakob disease with abnormal imaging. Arch Neurol 2006;63(2):288-290. doi:10.1001/archneur.63.2.288.
69. Jaunmuktane Z, Mead S, Ellis M, et al. Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy. Nature 2015;525(7568):247-250. doi:10.1038/nature15369.
70. Tousseyn T, Bajsarowicz K, Sánchez H, et al. Prion disease induces Alzheimer disease-like neuropathologic changes. J Neuropathol Exp Neurol 2015;74(9): 873-888. doi:10.1097/NEN. 0000000000000228.
71. Hamaguchi T, Sakai K, Noguchi-Shinohara M, et al. Insight into the frequent occurrence of dura mater graft-associated Creutzfeldt-Jakob disease in Japan. J Neurol Neurosurg Psychiatry 2013;84(10):1171-1175. doi:10.1136/jnnp-2012-304850.
72. Hamaguchi T, Sakai K, Noguchi-Shinohara M, et al. A comparative study of dura mater graft-associated Creutzfeldt Jakob disease between Japan and other countries. Prion 2015;9:S23YS24.
73. US Geological Survey. Chronic wasting disease. www.nwhc.usgs.gov/disease-information/chronic-wasting-disease/. Updated May 21, 2013, Accessed October 8, 2015.
74. Williams ES. Chronic wasting disease. Vet Pathol 2005;42(5):530-549. doi:10.1354/vp.42-5-530.
75. Safar JG, Lessard P, Tamgüney G, et al. Transmission and detection of prions in feces. J Infect Dis 2008;198(1):81-89. doi:10.1086/588193.
76. Haley NJ, Seelig DM, Zabel MD, et al. Detection of CWD prions in urine and saliva of deer by transgenic mouse bioassay. PLoS One 2009;4(3):e4848. doi:10.1371/journal.pone.0004848.
77. Wilson R, Plinston C, Hunter N, et al. Chronic wasting disease and atypical forms of bovine spongiform encephalopathy and scrapie are not transmissible to mice expressing wild-type levels of human prion protein. J Gen Virol 2012;93(pt 7):1624-1629. doi:10.1099/vir.0.042507-0.
78. Zimmer N, Boxal PC, Adamowicz WL. The impact of chronic wasting disease and its management on hunter perceptions, opinions, and behaviors in Alberta, Canada. J Toxicol Environ Health A 2011;72(22-24): 1621-1635. doi:10.1080/15287394. 2011.618988.
79. Walker LC, Jucker M. Neurodegenerative diseases: expanding the prion concept. Annu Rev Neurosci 2015;38:87-103. doi:10.1146/annurev-neuro-071714-033828.